Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis

The aim of the present study was to compare the efficacy of chemotherapy and support treatment in patients with advanced non-resectable gastric cancer in a systematic review and meta-analysis of randomized clinical trials that included a comparison of chemotherapy and support care treatment in patie...

Full description

Bibliographic Details
Main Authors: L. Casaretto, P.L.R. Sousa, J.J. Mari
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2006-04-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000400002
_version_ 1811202275407822848
author L. Casaretto
P.L.R. Sousa
J.J. Mari
author_facet L. Casaretto
P.L.R. Sousa
J.J. Mari
author_sort L. Casaretto
collection DOAJ
description The aim of the present study was to compare the efficacy of chemotherapy and support treatment in patients with advanced non-resectable gastric cancer in a systematic review and meta-analysis of randomized clinical trials that included a comparison of chemotherapy and support care treatment in patients diagnosed with gastric adenocarcinoma, regardless of their age, gender or place of treatment. The search strategy was based on the criteria of the Cochrane Base, using the following key words: 1) randomized clinical trials and antineoplastic combined therapy or gastrointestinal neoplasm, 2) stomach neoplasm and drug therapy, 3) clinical trial and multi-modality therapy, 4) stomach neoplasm and drug therapy or quality of life, 5) double-blind method or clinical trial. The search was carried out using the Cochrane, Medline and Lilacs databases. Five studies fulfilled the inclusion criteria, for a total of 390 participants, 208 (53%) receiving chemotherapy, 182 (47%) receiving support care treatment and 6 losses (1.6%). The 1-year survival rate was 8% for support care and 20% for chemotherapy (RR = 2.14, 95% CI = 1.00-4.57, P = 0.05); 30% of the patients in the chemotherapy group and 12% in the support care group attained a 6-month symptom-free period (RR = 2.33, 95% CI = 1.41-3.87, P < 0.01). Quality of life evaluated after 4 months was significantly better for the chemotherapy patients (34%; RR = 2.07, 95% CI = 1.31-3.28, P < 0.01) with tumor mass reduction (RR = 3.32, 95% CI = 0.77-14.24, P = 0.1). Chemotherapy increased the 1-year survival rate of the patients and provided a longer symptom-free period of 6 months and an improvement in quality of life.
first_indexed 2024-04-12T02:37:23Z
format Article
id doaj.art-1a6617fc98484ddd976a665b2ed81b0f
institution Directory Open Access Journal
issn 0100-879X
1414-431X
language English
last_indexed 2024-04-12T02:37:23Z
publishDate 2006-04-01
publisher Associação Brasileira de Divulgação Científica
record_format Article
series Brazilian Journal of Medical and Biological Research
spelling doaj.art-1a6617fc98484ddd976a665b2ed81b0f2022-12-22T03:51:28ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research0100-879X1414-431X2006-04-0139443144010.1590/S0100-879X2006000400002Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysisL. CasarettoP.L.R. SousaJ.J. MariThe aim of the present study was to compare the efficacy of chemotherapy and support treatment in patients with advanced non-resectable gastric cancer in a systematic review and meta-analysis of randomized clinical trials that included a comparison of chemotherapy and support care treatment in patients diagnosed with gastric adenocarcinoma, regardless of their age, gender or place of treatment. The search strategy was based on the criteria of the Cochrane Base, using the following key words: 1) randomized clinical trials and antineoplastic combined therapy or gastrointestinal neoplasm, 2) stomach neoplasm and drug therapy, 3) clinical trial and multi-modality therapy, 4) stomach neoplasm and drug therapy or quality of life, 5) double-blind method or clinical trial. The search was carried out using the Cochrane, Medline and Lilacs databases. Five studies fulfilled the inclusion criteria, for a total of 390 participants, 208 (53%) receiving chemotherapy, 182 (47%) receiving support care treatment and 6 losses (1.6%). The 1-year survival rate was 8% for support care and 20% for chemotherapy (RR = 2.14, 95% CI = 1.00-4.57, P = 0.05); 30% of the patients in the chemotherapy group and 12% in the support care group attained a 6-month symptom-free period (RR = 2.33, 95% CI = 1.41-3.87, P < 0.01). Quality of life evaluated after 4 months was significantly better for the chemotherapy patients (34%; RR = 2.07, 95% CI = 1.31-3.28, P < 0.01) with tumor mass reduction (RR = 3.32, 95% CI = 0.77-14.24, P = 0.1). Chemotherapy increased the 1-year survival rate of the patients and provided a longer symptom-free period of 6 months and an improvement in quality of life.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000400002Gastric cancerSystematic reviewCombined antineoplastic therapyCancer support treatmentMeta-analysisChemotherapy
spellingShingle L. Casaretto
P.L.R. Sousa
J.J. Mari
Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis
Brazilian Journal of Medical and Biological Research
Gastric cancer
Systematic review
Combined antineoplastic therapy
Cancer support treatment
Meta-analysis
Chemotherapy
title Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis
title_full Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis
title_fullStr Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis
title_full_unstemmed Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis
title_short Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis
title_sort chemotherapy versus support cancer treatment in advanced gastric cancer a meta analysis
topic Gastric cancer
Systematic review
Combined antineoplastic therapy
Cancer support treatment
Meta-analysis
Chemotherapy
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000400002
work_keys_str_mv AT lcasaretto chemotherapyversussupportcancertreatmentinadvancedgastriccancerametaanalysis
AT plrsousa chemotherapyversussupportcancertreatmentinadvancedgastriccancerametaanalysis
AT jjmari chemotherapyversussupportcancertreatmentinadvancedgastriccancerametaanalysis